Opposing actions of Arx and Pax4 in endocrine pancreas development

Patrick Collombat,¹ Ahmed Mansouri,¹ Jacob Hecksher-Sørensen,² Palle Serup,² Jens Krull,¹ Gerard Gradwohl,³ and Peter Gruss^{1,4}

¹Department of Molecular Cell Biology, Max-Planck Institute for Biophysical Chemistry, D-37077 Göttingen, Germany;

²Department of Developmental Biology, Hagedorn Research Institute, DK-2820 Gentofte, Denmark; ³Institut National de la Santé et de la Recherche Médicale U381, 67200 Strasbourg, France

Genes encoding homeodomain-containing proteins potentially involved in endocrine pancreas development were isolated by combined *in silico* and nested-PCR approaches. One such transcription factor, *Arx*, exhibits *Ngn3*-dependent expression throughout endocrine pancreas development in α , β -precursor, and δ cells. We have used gene targeting in mouse embryonic stem cells to generate *Arx* loss-of-function mice. *Arx*-deficient animals are born at the expected Mendelian frequency, but develop early-onset hypoglycemia, dehydration, and weakness, and die 2 d after birth. Immunohistological analysis of pancreas from *Arx* mutants reveals an early-onset loss of mature endocrine α cells with a concomitant increase in β - and δ -cell numbers, whereas islet morphology remains intact. Our study indicates a requirement of *Arx* for α -cell fate acquisition and a repressive action on β - and δ -cell destiny, which is exactly the opposite of the action of *Pax4* in endocrine commitment. Using multiplex reverse transcriptase PCR (RT-PCR), we demonstrate an accumulation of *Pax4* and *Arx* transcripts in *Arx* and *Pax4* mutant mice, respectively. We propose that the antagonistic functions of *Arx* and *Pax4* for proper islet cell specification are related to the pancreatic levels of the respective transcripts.

[**Keywords:** Endocrine pancreas development; *Arx*; *Pax4*; mouse; hypoglycemia; fate specification]

Received April 16, 2003; revised version accepted August 6, 2003.

The pancreas plays a major role in nutritional homeostasis through synthesis and secretion of hormones and enzymes. This organ includes endocrine, acinar, and ductal cell types, all deriving from a common set of epithelial cells that originate in the early gut endoderm. The exocrine pancreas develops to form acinar cells and a highly branched ductal epithelium, whereas endocrine cells aggregate into islets of Langerhans. The latter are specialized micro-organs composed of four different cell types, α , β , δ , and PP cells, which produce the hormones glucagon, insulin, somatostatin, and PP (pancreatic polypeptide), respectively. Insulin and glucagon function coordinately to control glucose homeostasis, whereas somatostatin and PP regulate the secretion of other hormones and of exocrine enzymes (Adrian et al. 1978; Roncoroni et al. 1983; Csaba and Dournaud 2001). The first morphological signs of pancreas development appear at embryonic day 9.5 (E9.5) as dorsal and ventral protrusions of the primitive gut epithelium that will later fuse to form the definitive pancreas (for review, see Edlund 2002). Concomitantly, the glucagon-producing α cells are the first endocrine cells detected (Herrera et al. 1991; Teitelman et al. 1993; Upchurch et al. 1994). One

day later (E10.5), a few insulin-producing cells appear, often coexpressing glucagon (Teitelman et al. 1993). At E14, the secondary transition, as defined by Pictet and Rutter (Pictet et al. 1972), leads to the generation of numerous fully differentiated β cells. Endocrine cells start to become organized in small aggregates, and within the next 24 h, the first somatostatin-producing δ cells emerge (Pictet et al. 1972). Finally, at E18, shortly before birth, PP-producing cells differentiate, whereas endocrine cells begin to form well-organized islets of Langerhans.

Until recently, the mechanisms underlying the generation of these different endocrine cell types was not well understood, but lineage studies and the generation of mice deficient for a number of pancreatic transcription factors have provided major insights into the control of islet development. One such transcription factor is *Neurogenin3* (*Ngn3*), a basic helix-loop-helix (bHLH) protein-encoding gene member of the neurogenin/neuroD family, which is first detected in the pancreatic epithelium at E9 (Sommer et al. 1996; Apelqvist et al. 1999; Jensen et al. 2000; Schwitzgebel et al. 2000). *Ngn3* loss-of-function mutant mice fail to develop endocrine cells (Gradwohl et al. 2000), whereas ectopic expression of *Ngn3* under the control of the *pdx1* promoter leads to the differentiation of the entire pancreas into endocrine cells (Apelqvist et al. 1999; Schwitzgebel et al. 2000). The pro-endocrine function for *Ngn3* suggested by these data was

⁴Corresponding author.

E-MAIL peter.gruss@mpg-gv.mpg.de; FAX 49-551-201-1504.

Article and publication date are at <http://www.genesdev.org/cgi/doi/10.1101/gad.269003>.

further demonstrated by lineage studies using the Cre/LoxP system (Gu et al. 2002). Hence, whereas *Ngn3* activation in pancreatic progenitor cells promotes an endocrine commitment, the specification of the four different islet subtypes appears to be controlled by other genes. A number of homeodomain-containing transcription factors have been characterized for their implication in each of the pathways leading to differentiated endocrine cell subtypes using loss-of-function mutant mice. Two groups can be distinguished on the basis of their colocalization with *Ngn3*; the early factors found in *Ngn3*-expressing cells (*Nkx2.2*, *Nkx6.1*, *Pdx1*, and *Pax4*) and the late factors (*Brn4*, *Isl1*, and *Pax6*) present in mature endocrine cells that are devoid of *Ngn3* expression (Jensen et al. 2000; Schwitzgebel et al. 2000).

The paired-box-containing factor *Pax4* is selectively expressed in the developing islets of Langerhans and is later restricted to mature endocrine cells (Smith et al. 1999; Dohrmann et al. 2000). *Pax4*-deficient mice develop severe diabetes at birth as a result of altered islet cell development characterized by a deficiency of β and δ cells, together with an increase of the α -cell population (Sosa-Pineda et al. 1997). Similarly, the NK-homeodomain protein-encoding genes, *Nkx6.1* and *Nkx2.2*, are required for endocrine specification. Mice homozygous for a targeted deletion of either gene have a reduced number of β cells. In addition, a decrease in the number of α and PP cells is found in *Nkx2.2* mutant mice. *Nkx6.1* expression is abolished in these animals, suggesting that *Nkx2.2* acts upstream *Nkx6.1* (Sussel et al. 1998; Sander et al. 2000).

In contrast, the late factors *Brain-4*, *Isl1*, and *Pax6* act on the development and the maintenance of differentiated islet cells. Targeted disruption of the paired-box-containing gene *Pax6* or of the LIM homeodomain protein-encoding gene *Isl1* leads to a drastic reduction of all endocrine subtypes (Ahlgren et al. 1997; Sander et al. 1997; St-Onge et al. 1997). *Brain-4* (*Brn-4*), a POU-homeodomain-containing protein, is expressed in the pancreatic anlage of the mouse foregut at E10 in glucagon-producing cells and seems to transactivate glucagon gene expression (Hussain et al. 1997). However, loss-of-function mutant mice do not exhibit any defect in α -cell formation (R.S. Heller and P. Serup, in prep.), although ectopic expression of *Brn-4* targeted to β cells leads to the coexpression of insulin and glucagon in this cell type (Hussain et al. 2002). These data suggest a role of *Brn4* in the advanced islet to promote hormone expression. Similarly, *Pdx1*, a homeodomain-containing protein involved in pancreatic bud formation (Jonsson et al. 1994; Guz et al. 1995; Offield et al. 1996), plays an additional role in maintaining the β -cell phenotype. Using the Cre/Lox system, Ahlgren et al. (1998) demonstrated that β -cell-targeted deletion of *Pdx1* leads to the loss of this cell type. Taken together, these data suggest that islet progenitors are progressively committed to an islet fate, specified to a particular endocrine cell subtype and finally maintained in this commitment.

In this study, we describe the functional characteriza-

tion of *Arx* in the endocrine pancreas. The homeobox-containing gene, *Arx*, which is localized on the X chromosome (Blair et al. 2002), was first reported to be expressed in the mouse central nervous system (CNS) by Miura et al. (1997). Recently, *Arx* dysfunction has been associated with diverse forms of X-linked mental retardation and epilepsy in humans (discussed in Hirose and Mitsudome 2003). Interestingly, by means of in situ hybridization, we observed a previously unnoticed expression in the pancreas, at the onset of pancreatic bud evagination, which later becomes restricted to the islets of Langerhans. To investigate the role of this gene in pancreas development, we generated loss-of-function mutant mice. *Arx*-deficient animals die 2 d after birth, after having developed severe hypoglycemia. Immunohistochemical analysis of *Arx* mutant pancreas revealed an absence of α cells and an increased number of β and δ cells. However, the total number of endocrine cells is unaffected, suggesting a role for *Arx* in promoting α -cell fate. This is opposite to the phenotype observed in *Pax4*-deficient mice, and we demonstrate that a mutual inhibition of *Arx* and *Pax4* during early stages of endocrine development is required to generate normal islets of Langerhans.

Results

Arx is expressed in endocrine pancreas progenitors

Aiming to identify members of the homeobox-containing gene family with a potential role in islet of Langerhans genesis, we undertook a search combining in silico and nested-PCR, using a mouse cDNA pancreas library as a template (P. Collombat, A. Mansouri, and P. Gruss, in prep.). Several genes with previously unnoticed expression in this organ were isolated, including *Arx*, a gene encoding a homeodomain-containing protein. *Arx* expression was described previously in the mouse central nervous system, starting from E9.5 (Miura et al. 1997). Importantly, at this particular stage, we detected expression of *Arx* in the pancreas anlage (Fig. 1A, arrowhead in B). *Arx*-expressing cells were found during the genesis of this organ, in the proliferating epithelium (Fig. 1C), the differentiating pancreatic precursors (Fig. 1D), and subsequently, in the forming islets of Langerhans (Fig. 1E).

To determine whether *Arx* played a role in endocrine cell development, *Arx* expression was studied in the pancreas of mice mutant for the pro-endocrine *Ngn3* gene. At E14.5, just before the peak of endocrine cell production, examination of the pancreas of *Ngn3* mutant embryos revealed a complete loss of *Arx* expression (Fig. 1G,I). This result was further confirmed by RT-PCR performed in wild-type and *Ngn3* mutant pancreas (Fig. 1, RT-PCR panel). Taken together, our data indicate new expression domains of *Arx* in the developing pancreas. Notably, the lack of *Arx* transcripts in the pancreas of *Ngn3*-deficient mice suggests a potential role of *Arx* downstream of *Ngn3* in islet of Langerhans developmental processes.

Figure 1. *Arx* is expressed in normal mouse pancreas, but not in that of *Ngn3*-deficient animals. (A,B) Whole-mount in situ hybridization of an E9.5 mouse embryo. Sagittal section (A) and enlarged view of the pancreatic area (B), revealing *Arx* transcripts in the pancreas anlage (arrowhead in B). (C–E) When analyzed by in situ hybridization, pancreas sections display widespread *Arx* expression at E12.5 (C), E14.5 (D), and E16.5 (E). (F–I) Detection of *glucagon* and *Arx* expression by in situ hybridization in E14.5 wild-type (F,G) and *Ngn3* homozygous mutant animals (H,I). *Ngn3* mutant pancreas lacks *Arx* expression. (RT–PCR) RT–PCR analysis performed on mRNA from E14.5 wild-type or *Ngn3* mutant animals (left and middle lanes, respectively). RT–PCR controls were performed with primers designed from the *glucose-6-phosphate dehydrogenase* (*G6PDH*) and the *TATA-box-binding protein* (*TBP*) reference genes; positive controls with primers from the *amylase* gene and negative controls were assayed with water instead of DNA template (right lane). RT–PCR results confirm a lack of *glucagon* and *Arx* expression in *Ngn3* mutant mice.

Generation of *Arx* loss-of-function mutant mice

To gain insight into the potential function of *Arx* during pancreas development, we generated loss-of-function mutant mice by homologous recombination in embryonic stem (ES) cells. A targeting vector was designed to delete the two first exons corresponding to the N-terminal 360 amino acids (Fig. 2A). These two exons, which encode the octapeptide (Eh1 domain), α -helix 1 and approximately half α -helix 2 of the homeodomain, were replaced by the β -galactosidase gene and the *Neomycin resistance* gene flanked by LoxP sites. Of the 202 stably transfected ES clones obtained after antibiotic selection, two were homologous recombinants as identified by Southern analysis (Fig. 2B). Because the *Arx* gene is localized on the X chromosome (Blair et al. 2002), and ES cells were derived from male blastocysts, we therefore detected either the wild-type (designated as X⁺) or the mutated (designated as X⁻) allele. Chimeras obtained from the targeted ES cell clones were bred to NMRI mice with successful germ-line transmission. Heterozygous X⁺/X⁻ females of the mixed background (129Sv $\times$ NMRI) were crossed with wild-type males (X⁺/Y), and both sex and genotype of the offspring were determined by PCR (Fig. 2C). In situ hybridization demonstrated that our targeting approach deleted the *Arx* gene, as its expression was undetectable using a full-length cDNA-derived

probe (Fig. 2D, bottom). The following allelic frequencies were obtained: 52.3% wild-type (X⁺/X⁺ females and X⁺/Y males), 24.2% heterozygous (X⁺/X⁻ females), and 23.5% null (X⁻/Y males; $n = 189$); such a Mendelian ratio indicates that the deletion of the *Arx* gene did not result in embryonic lethality. No obvious difference was observed between heterozygous and wild-type animals. We therefore used mice of both genotypes as controls throughout this study.

Arx-deficient mice exhibit severe hypoglycemia prior to death

Arx loss-of-function mutant mice have been described previously (Kitamura et al. 2002). They are born at E19.5 and die within 12 h. Compared with wild-type animals, they have a small brain, reduced olfactory bulbs, and altered testes. However, the precise cause of death was not ascertained.

The *Arx*-deficient mice generated in the present study (X⁻/Y males) are indistinguishable from wild-type or heterozygous littermates at birth. Phenotypic discrepancies appear within the first day postpartum; despite normal feeding, as evidenced by the presence of milk in the stomach, *Arx* mutants display retarded growth, are dehydrated, and die at postnatal day 2 (P2; Fig. 2D, top).

The different phenotypic alterations exhibited by the *Arx* mutant mice generated by Kitamura et al. (2002), such as early birth and shortened life-span, most probably originate in the different targeting strategies; thus, Kitamura et al. (2002) inserted a STOP-IRES-LacZ-Neomycin resistance cassette downstream of the second exon of the *Arx* gene. Consequently, it cannot be excluded that a gain-of-function mutation was generated. In contrast, our knockout construct was generated by specifically deleting the two first exons. We further demonstrate the absence of full-length *Arx* transcripts by in situ hybridization and RT-PCR analysis (Fig. 2D, bottom; data not shown).

To determine whether the observed lethality was related to anomalous endocrine pancreatic function, blood glucose levels were measured. Twelve hours after birth, glycemia appeared normal in all littermates (Fig. 2E). The first differences were observed 1 d postpartum; whereas wild-type and heterozygous animals displayed a normal blood glucose level, that of the mutants was slightly decreased. However, 2 d after birth, the mice lacking a functional *Arx* gene exhibited a severe hypoglycemia (46.72 ± 14 mg/dl, $n = 36$), which dropped sharply shortly before death (<10 mg/dl, $n = 26$), in contrast to age-matched wild-type (85.67 ± 12 mg/dl, $n = 26$) and heterozygous (80.72 ± 11 mg/dl, $n = 32$) animals.

Arx mutant mice display a loss of mature α cells concomitant with an increase in β - and δ -cell numbers

To decipher the role of *Arx* in endocrine pancreatic differentiation, histological analysis of pancreas from 2-day-old control and *Arx* mutant mice was performed. The general morphology of the pancreas and the islets of Langerhans appeared normal (Fig. 3A,B). Similarly, a kinetic analysis in islets, using X-Gal staining, recapitulated the previously observed *Arx* expression pattern, both in heterozygous and mutant animals (Miura et al. 1997; data not shown). More specifically, X-Gal-stained cells were detected in the pancreatic epithelium as early as E10.5 (Fig. 3C–F). An expansion of pancreatic β -galactosidase-labeled cells was seen between this stage and E16.5, together with endocrine cell development (Fig. 3G,J). The first discrepancies between heterozygous and mutant *Arx* mice arise at this stage and persist after birth with an increase in the number of X-Gal-positive cells in mutant animals (Fig. 3I–L).

Islets were further subjected to a molecular phenotype analysis using immunohistochemistry to detect the presence of endocrine cell-subtypes producing insulin, glucagon, somatostatin, or PP. Strikingly, P2 *Arx*-deficient animals were completely lacking glucagon-producing α cells in the islets of Langerhans (Fig. 4D,M). We were not able to detect any glucagon-producing cells, even using higher antibody concentrations or different glucagon antibodies (data not shown). Concomitantly, there was a dramatic increase in the somatostatin-producing cell population of *Arx* mutant animals (Fig. 4E,N). Colocalization experiments with β cells allowed

Figure 3. *Arx* expression assessed by LacZ staining demonstrates an increase in the number of β -galactosidase-producing cells within the islet of Langerhans in *Arx*-deficient mice. (A,B) Hematoxylin-eosin staining of 2-day-old pancreas sections reveals no morphological discrepancy between heterozygous (A) and mutant (B) *Arx* mice. (C,D) Whole-mount LacZ staining of *Arx*-deficient embryos (C) and enlarged view (D) reveals β -galactosidase expression in the pancreas as early as E10.5, as well as in additional hitherto unmentioned domains. Pancreas sections of heterozygous (E,G,I,K) and mutant (F,H,J,L) *Arx* animals were examined for β -galactosidase activity by X-Gal staining at different developmental stages as follows: E10.5 (E,F, outlined), E12.5 (G,H), E16.5 (I,J), and P2 (K,L). β -galactosidase-positive cells present a similar distribution at early embryonic stages in wild-type and mutant pancreas. After E16.5, the content of β -galactosidase-producing cells is increased in mutant animals as compared with littermates. Each picture is representative of at least eight animals from different litters.

us to clearly demonstrate that δ cells also exhibited an abnormal distribution within the islet of Langerhans. In normal pancreas, at approximately E18, endocrine cell aggregates begin to develop the architecture of mature islets (Slack 1995), characterized by a core of β cells surrounded by a mantle of α , δ , and PP cells (Fig. 4G–I). In *Arx* mutants, δ cells were no longer localized to the

Figure 4. Increased δ - and β -cell populations at the expense of α cells in *Arx*-deficient mice. Single sections of 2-day-old mice were examined for the presence of pancreatic hormone in control (A–I) and *Arx* mutant (J–R) animals by coimmunofluorescence. (A–C, J–L) Insulin-expressing cells were localized in well-defined islets using 488-ALEXA secondary antibody. Codetection experiments were performed with 594-ALEXA secondary antibody to visualize either glucagon-producing cells (D, M), somatostatin-producing cells (E, N), or PP-producing cells (F, O), and sections were counter-stained with DAPI (G–I, P–R, in blue). (G–I, P–R) A picture combining codetection of β cells with other endocrine cells and counter-staining is provided in each case. Note the slight increase of the insulin-producing cell population (cf. A–C and J–L), the loss of glucagon-secreting cells (cf. D and M), and the increase in the number of somatostatin-expressing cells (cf. E and N) in *Arx* mutant animals. *Arx* deletion also leads to a modification of the spatial distribution of δ cells with an additional localization within the islet core (cf. E, H and N, Q). Each picture is representative of 8–20 animals from different litters.

mantle zone, but could be seen scattered in the core of the islet (Fig. 4E, H, N, Q). In addition, we observed a slight increase of insulin-producing β -cell number within the islets of Langerhans (Fig. 4A–C, J–L), whereas the number of PP-producing cells appeared normal (Fig. 4F, O). To confirm and quantify these differences, we serially sectioned whole P2-pancreas and determined the number of insulin-, glucagon-, somatostatin-, and PP-positive cells in every tenth section. The data from this analysis confirm the complete loss of glucagon-producing cells in mutant mice, whereas the mean number of somatostatin- and insulin-expressing cells per section was increased, 2-fold and 1.3-fold, respectively, in *Arx* mutants as compared with their heterozygous or wild-type littermates (Table 1). The average PP-cell number per section was not modified significantly. Collectively, our data indicate that *Arx* deficiency does not alter the general morphology of the pancreas and suggest that *Arx* function is specifically required for the proper apportionment of α -, β -, and δ -cell numbers, as well as appropriate location of the latter.

Arx is differentially required for α -, β -, and δ -cell specification

To determine when the phenotypic alterations observed in *Arx*-deficient islets occur, we examined the pancreas of control and mutant embryos at earlier stages of development for the presence of endocrine hormones and β -galactosidase. At E10.5, the number of glucagon-expressing cells appeared normal (data not shown). Insulin-expressing cells were observed in mutant pancreas at this stage, but we were unable to determine whether their number was altered because very few cells are present at this stage, even in wild-type mice. However, at E12.5, when both insulin- and glucagon-expressing cells are readily detectable in the normal pancreas, glucagon-producing cells, often coexpressing the insulin hormone, were detected in *Arx* mutant pancreas in normal proportions (Fig. 5A, B). Importantly, none of these hormone-secreting cells coexpressed the β -galactosidase enzyme in the islets of Langerhans of both genotypes (Fig. 5C, D; data not shown). These results provide evidence that *Arx*

Table 1. Quantification of pancreatic endocrine cell content alterations in *Arx*-deficient mice

Hormone-producing cells	Endocrine cell distribution in <i>Arx</i> mutant mice		Percent difference
	Wild-type, <i>Arx</i> heterozygotes	<i>Arx</i> hemizygotes	
Insulin	307 ± 35 (61%)	404 ± 23 (74%)	+31
Glucagon	143 ± 26 (28%)	0	—
Somatostatin	44 ± 14 (9%)	135 ± 28 (25%)	+207
Pancreatic polypeptide	9 ± 4 (2%)	8 ± 3 (1%)	~0
Total cells	503 ± 79	547 ± 54	~0

Endocrine cells were counted from immunostained sections of 2-day-old pancreas estimated to be the same size. Data are shown as the mean number ± S.E. of the mean (S.E.M.) of hormone-positive cells per section (every tenth section) from at least three independent pancreata. Percentages in brackets indicate the contribution of a particular endocrine cell-subtype to the total islet cell population. Hemizygous *Arx* pancreas lacks α cells, whereas β- and δ-cell content are increased 1.31- and 2.07-fold, respectively. Importantly, the total endocrine cell number is unchanged following *Arx* distribution.

is not implicated in the generation of early insulin/glucagon-producing cells.

In contrast, when assayed at E15.5, islets of Langerhans in *Arx*-deficient mice were found to be completely

lacking glucagon-expressing cells (Fig. 5E,F). At the same time, an increase of the insulin-producing cell population was clearly apparent (Fig. 5G–J). β-galactosidase labeling was detected in all α cells in heterozygous pancreas using protein and mRNA detection (Fig. 5E; data not shown). However, in both genotypes, β cells did not possess detectable β-galactosidase mRNA (Fig. 5G,H). Interestingly, when sections of pancreas of control and mutant mice were stained with antibodies di-

Figure 5. Alteration of mature endocrine cell-subtype specification following *Arx* inactivation. (A–D) Staining of E12.5 heterozygous (A,C) and mutant (B,D) *Arx* pancreata for insulin (A,B), glucagon (C,D), and β-galactosidase (E,F) proteins, counter-stained with DAPI (blue). β-galactosidase is not expressed in the early hormone-producing cells. There is no change in the number of insulin-expressing cells (often producing glucagon) following *Arx* deletion. (E–L) Sections of pancreas from E15.5 (E–J) and E18.5 (K,L) stained with anti-β-galactosidase (E,F,I–L), anti-glucagon (E,F), anti-Nkx6.1 (G,H), anti-DIG (G,H, shown in red), anti-insulin (I,J), or anti-somatostatin (K,L) antisera and counter-stained with DAPI (blue) in heterozygous (E,G,I,K) or mutant (F,H,J,L) animals except in G and H. (E,F) Glucagon-secreting cells coexpress β-galactosidase and are lacking in mutant pancreas. (G,H) β cells (stained with Nkx6.1 for technical reasons) do not express β-galactosidase in E15.5 mutant and control pancreas. (I,J) The β-cell population is increased in mutant islets. A residual presence of β-galactosidase protein is observed. (K,L) β-galactosidase staining is detected in δ cells, which are overrepresented in E18.5 *Arx*-deficient mice. (M–R) Endocrine differentiation appears normal following *Arx* inactivation. Sections of heterozygous (M,O,Q) and mutant (N,P,R) pancreas were stained with anti-Pax6 (M,N), anti-Ngn3 (O,P), or anti-Is11 (Q,R) antisera together with anti-β-galactosidase antisera and counter-stained with DAPI (blue). (M,N) All β-galactosidase-labeled cells coexpress Pax6. Pax6-marked cells are normally represented in both genotypes. (O,P) Arrows show a few *Arx*- and Ngn3-labeled cells. *Arx* deletion does not alter the numbers of Ngn3-stained cells. (Q,R) Is11-marked cells are exclusively found among the β-galactosidase-labeled population, but numerous cells are β-galactosidase+/Is11–, suggesting a function of *Arx* in nonmature cells. Similar numbers of Is11+ cells are observed in control and *Arx* mutant pancreas. Each picture is representative of at least three animals from different litters.

rected against β -galactosidase and insulin proteins, we observed residual β -galactosidase proteins in insulin-producing cells of *Arx*-deficient embryos (Fig. 5I,J). Because the stability of the β -galactosidase protein allows the latter to be used as a short-term lineage tracer, our results suggest that β -galactosidase-expressing β cells observed in mutant animals derive from *Arx*-depleted cells. δ cells were also positive for β -galactosidase protein and mRNA (Fig. 5K,L; data not shown). As early as E18.5, *Arx*-depleted animals had developed more somatostatin/ β -galactosidase-labeled cells than control mice, suggesting that *Arx*-deficient cells also adopt a δ -cell fate.

To further elucidate the molecular nature of the defects observed following *Arx* deletion, an extensive immunohistochemical analysis of the transcription factors involved in endocrine determination was performed. Sections of E14.5 pancreas were first incubated with antisera against β -galactosidase together with antisera against the Pax6, Ngn3, or Isl1 proteins (Ahlgren et al. 1997; Sander et al. 1997; Gradwohl et al. 2000). In control and *Arx* mutant animals, β -galactosidase staining was detected in Pax6-positive cells (Fig. 5M,N), Ngn3-labeled cells (Fig. 5O,P, arrowheads), and the vast majority of Isl1-stained cells (Fig. 5Q,R). Interestingly, the total numbers of Pax6-, Ngn3-, and Isl1-marked cells were not modified following *Arx* deletion. Similarly, examination of the expression of various additional transcription factors shown previously to play a role in endocrine cell specification, such as Nkx2.2, Nkx6.1, Pdx1, and HB9 (Harrison et al. 1994; Sussel et al. 1998; Li et al. 1999; Sander et al. 2000), demonstrated that they were all present and appropriately localized in heterozygous and mutant *Arx* animals.

Taken together, our results demonstrate the presence of two distinct populations of insulin- and glucagon-labeled cells during pancreas development. *Arx* does not act on the generation of the early hormone-producing cells. Instead, it is required for the specification of mature endocrine cells, as evidenced by the increased population of β and δ cells and the loss of α cells in *Arx*-deficient mice. In addition, similar numbers of Ngn3-stained endocrine precursors and Isl1-labeled postmitotic endocrine cells were detected in control and mutant mice. Importantly, no alteration in the total islet cell number was detectable after birth. We therefore conclude that the lack of a functional *Arx* allele causes α -cell progenitors to adopt an alternative β - or δ -cell fate.

Arx and Pax4 are up-regulated in Pax4 and Arx mutant mice, respectively

Strikingly, the deduced instructive function of *Arx* in specifying α -cell-subtype fate at the expense of β - and δ -cell destiny is the reverse of that attributed to the paired-box-containing factor Pax4. Mice homozygous for a mutant allele of *Pax4* also exhibit an altered pancreatic endocrine cell-subtype ratio, characterized by an increased α -cell population and drastically reduced β - and δ -cell numbers (Sosa-Pineda et al. 1997). Such opposing phenotypic alterations are strongly suggestive of antago-

nistic functions of Pax4 and *Arx* during endocrine specification. To shed light on potential cross-regulatory functions of Pax4 and *Arx* in this phenomenon, we assayed pancreatic *Pax4* and *Arx* mRNA content by multiplex RT-PCR in *Arx* and *Pax4*-deficient mice, respectively. The pancreas of *Pax4* mutant animals contained 3.3 times more *Arx* mRNA than the control at E14.5 (Fig. 6A), whereas the content of *Pax4* transcripts was four-fold higher in the pancreas of *Arx*-depleted mice (Fig. 6B). Hence, our data clearly demonstrate that *Arx* inactivation results in an accumulation of *Pax4* transcripts associated with an increased number of β and δ cells. Conversely, *Pax4* inactivation is accompanied by a rise in *Arx* mRNA levels, leading to an over-representation of the α cells in mature islets. We conclude that *Arx* and Pax4 have opposing actions on the specification of endocrine subtype destiny through an inhibitory cross-regulatory circuit that controls the transcriptional state of these two genes.

To determine whether this interaction reflects mechanisms involving individual or different cells, we analyzed *Arx* and Pax4 at the single-cell level. Due to the lack both of a suitable *Pax4* antisense probe and of an antibody directed against Pax4, we assayed *Pax4* expression using the β -galactosidase reporter gene present in heterozygous *Pax4* pancreas. The recent generation of an anti-*Arx* antibody (recapitulating the *Arx* expression pattern, as demonstrated in Fig. 6C,D) allowed us to co-detect *Arx* and Pax4 proteins in single islet cells as early as E13.5 (Fig. 6E). As the proliferation of glucagon and insulin-expressing cells proceeds, *Arx* and Pax4 were found to be coexpressed, but in 27% less cells (arrows in Fig. 6F), whereas the number of cells expressing either *Arx* or β -galactosidase increases. These data suggest that *Arx* and Pax4 are first found together in endocrine progenitors, however, as development continues, one of the factors prevails and the predominant protein will determine the fate of the endocrine cell. To find out whether this is achieved through direct interaction between Pax4 and *Arx*, we also examined *Arx* expression in *Pax4*-deficient embryos at E14.5 (Fig. 6G). We observed a 64% increase in the number of cells doubly positive for β -galactosidase and *Arx* proteins (Fig. 6, cf. F and G), thereby further demonstrating that *Arx* expression is up-regulated in the absence of functional Pax4.

Discussion

In this study, the consequences of the loss-of-function of the *Arx* gene on the differentiation of the endocrine pancreas are presented. In fact, although *Arx* has been inactivated previously in the mouse, resulting in abnormal differentiation and proliferation of the brain and testes, no expression or defect in the pancreas has been described (Kitamura et al. 2002). Our analysis clearly establishes that *Arx* transcripts are detectable as early as E9.5 in the pancreatic epithelium and are later found in mature α and δ cells. Mice carrying a targeted disruption of the *Arx* gene develop severe hypoglycemia, weakness, dehydration, and die 2 d after birth. Detailed examina-

Figure 6. Increase of *Arx* and *Pax4* transcript levels in the pancreas of *Pax4*- and *Arx*-deficient mice, respectively. Multiplex amplification of pancreatic mRNA from *Pax4*- (A) and *Arx*- (B) mutant mice at E14.5. The genotypes of control and mutant mice are indicated above the gel scans. Measurements of the intensity of radioactive *Arx* and *Pax4* PCR products, after normalization with the coamplified TATA-box-binding protein (TBP) amplicon, are represented as graphs. Below are indicated the average normalized intensities in control and mutant mice as well as their relative difference; the *Arx* transcript content is 3.3-fold higher in E14.5 *Pax4* mutant pancreas compared with control animals. *Arx*-deficient pancreas contains four times more *Pax4* mRNA at the same embryonic stage. (C,D) An anti-*Arx* antibody recapitulates *Arx* expression pattern at E11.5 (sagittal section in C and enlarged picture in D) in the forebrain (FB) and the floor plate of the diencephalon (Fp). (E–G) Analysis of *Arx* (red) and β-galactosidase (green) expression in *Pax4* heterozygous (E,F) and homozygous (G) pancreas. The average percentage of *Arx*⁺/β-galactosidase⁺ cells from three serially sectioned pancreata is indicated below each picture. (E) In *Pax4* heterozygous pancreas, *Arx* is found colocalized with the β-galactosidase protein at E13.5 in 35% of endocrine cells. (F) At E14.5, only 8% of islet cells are *Arx*⁺/β-galactosidase⁺. (G) At the same stage, in *Pax4* homozygous pancreas, this number increases with a codetection of *Arx* and β-galactosidase found in 72% of the endocrine cells.

tion of the pancreas reveals an early-onset loss of the mature α-cell population, concomitant with an augmentation of β- and δ-cell types, as well as an abnormal distribution within islets for the latter subtype.

Role of *Arx* in endocrine specification

By irreversibly tagging the progeny of cells via the Cre/LoxP system, Herrera (2000) clearly demonstrated that adult glucagon- and insulin-producing cells do not derive from cells that coexpressed both hormones previously, but rather emerge through distinct pathways. This study suggests that, throughout the development of the islet of Langerhans, two different populations of insulin-producing cells are generated successively, as well as two distinct types of glucagon-expressing cells. Other data have confirmed the existence of two insulin-expressing cell populations (Oster et al. 1998; Sander et al. 2000), and our results corroborate this finding. Importantly, we also clearly demonstrate the presence of two distinct glucagon-expressing cell types. In *Arx* mutant islets of Langerhans, the development of the early glucagon-/insulin-

expressing cells remains unaffected, but mature α cells fail to appear at later stages, whereas the number of mature β and δ cells is increased. Interestingly, *Arx* labeling was observed at an early developmental stage, but never in hormone-expressing cells. In contrast, *Arx* expression was detected after E14.5, in α, β-precursors, and later in δ cells, further demonstrating that mature endocrine cells emerge from endocrine progenitors that did not express hormone previously.

Our finding that in *Arx*-deficient embryos α-, β-, and δ-cell content is significantly modified without alteration in shape, size, or total endocrine cell number suggests a replacement of the mature α cells by δ and β cells. Accordingly, *Arx* seems to determine the relative fate of these cells. This hypothesis is reinforced by the loss of *Arx* expression in the pancreas of *Ngn3*-deficient mice and the fact that pancreas from *Arx* mutant mice contains normal proportions of early *Ngn3*-labeled endocrine progenitors and *Isl1*-marked post-mitotic endocrine cells, as well as *Nkx2.2*-, *Nkx6.1*-, *Pdx1*-, and *HB9*-positive cells. Taken together, our data demonstrate that in *Arx*-deficient animals, β-, δ-, and PP-cell developmen-

tal processes are normal and lead to the generation of well-formed islets of Langerhans. However, α cells fail to appear, whereas β - and δ -cell numbers are increased. We conclude that *Arx* promotes the acquisition of α -cell fate by endocrine progenitors and does so by antagonizing β - and δ -cell commitment.

Arx and Pax4 act as differential regulators of endocrine cell fate

The results presented above indicate that *Arx* plays a key role in differential specification of islet cells. However, little is known of the processes underlying such a function; only the *Pax4* gene has been shown to act differentially on endocrine cell destiny (Sosa-Pineda et al. 1997), as *Pax4* deletion leads endocrine progenitors to adopt an alternative cell-subtype fate. The modifications of the islet-cell subtype content observed in these mutant mice are reminiscent of those seen in *Arx* loss-of-function mutant animals. *Pax4*- and *Arx*-depleted pancreas displays inversed alterations in α -, β -, and δ -cell ratio. The abnormalities seen in *Arx*- and *Pax4*-deficient mice suggest antagonistic roles for these two transcription factors. Using multiplex RT-PCR, we established that *Pax4* mRNA is up-regulated in *Arx* mutant mice, and that the *Arx* transcript content is increased in *Pax4*-deficient pancreas. Furthermore, the recent generation of an anti-*Arx* antibody allowed us to demonstrate that *Arx* and *Pax4* (the latter assayed by β -galactosidase staining in heterozygous *Pax4* animals) are colocalized in early endocrine pancreas, but not at later developmental stages. Interestingly, our data suggest that in endocrine progenitors, one of these factors will ultimately predominate; if it is *Pax4*, β - and δ -cell fates will be specified, whereas *Arx* will favor α -cell commitment. Hence, we conclude that proper islet of Langerhans formation requires a tight control of the relative levels of *Arx* and *Pax4* mRNA, probably achieved via mutual inhibition.

Our data, together with the results obtained by others (Sander et al. 1997; Sosa-Pineda et al. 1997; Mansouri et al. 1999; Gradwohl et al. 2000), allow us to propose the model depicted in Figure 7. In endocrine progenitors, *Arx* promotes α -cell fate and antagonizes β - and δ -cell destiny, whereas *Pax4* favors β - and δ -cell fates at the expense of α -cell destiny. Our results suggest that these opposing activities are the consequences of a mutual cross-regulatory inhibition of these factors. The detailed mechanisms involved remain to be elucidated. Similarly, further work will be required to determine potential downstream target genes of *Pax4* and *Arx* involved in endocrine subtype determination. In this respect, a recent study by Huotari et al. (2002) has implicated EGF signaling. Using pancreatic explant cultures, the authors have demonstrated that the EGF receptor family-binding proteins Betacellulin and Neuregulin-4 promote β - and δ -cell fates, respectively, in each case, at the expense of α -cell destiny. These results are consonant with the phenotype of *Arx* loss-of-function mice. To decipher the mechanisms involved in endocrine subtype commitment, a thorough examination of (1) *Arx* and *Pax4* ex-

Figure 7. Schematic model representing the transcription factors implicated in the specification of the endocrine pancreas, on the basis of temporal expression and phenotypic results of specific gene deletions. Circles represent endocrine cells at particular developmental stages. The different transcription factors expressed in a particular cell type are indicated within the circles. Arrows represent different (hypothetical) endocrine differentiation steps. Loss-of-function mutant mice phenotypes demonstrate antagonistic endocrine-specifying activities for *Arx* and *Pax4*; *Pax4* promotes β - and δ -cell fates, whereas *Arx* favors α -cell destiny. The question mark indicates a fate remaining to be elucidated. For the purpose of simplification, exocrine/ductal- and PP-cell development are not represented.

pression in mice with perturbed ErbB signaling and (2) EGF signaling in *Arx* and *Pax4* mutant mice would be of particular interest. Similarly, the double inactivation of *Arx* and *Pax4* and ectopic expression of either gene would permit us to unravel the interaction between these two factors.

In summary, our analysis establishes a requirement of *Arx* for proper endocrine cell specification. We provide strong evidence that *Arx* and *Pax4* play opposite roles in this process. Because the islet hormones, especially insulin and glucagon, have a central function in nutriment metabolism, alterations in the expression of *Arx* in the islets of Langerhans could modify nutriment homeostasis in the whole organism. Mutations of the human *ARX* gene have been associated with a particular type of X-linked lissencephaly with abnormal genitalia (Kitamura et al. 2002); it would be interesting to determine whether mutations in the human *ARX* gene are, additionally or independently, associated with glucose homeostasis deregulation.

Material and methods

Targeted disruption of the Arx gene

To generate *Arx* mutant mice, two overlapping clones containing the entire *Arx* gene were isolated from a 129/Sv mouse

genomic library (provided by Anton Berns, Amsterdam). The gene was mapped using a combination of Southern analysis and restriction enzyme digests. The targeting construct is depicted in Figure 2A. Briefly, aiming to delete the ATG start-codon without altering any potential regulatory element, a 2.0-kb digested *HindIII/EcoRV* 5' fragment was ligated to a 450-bp PCR-amplified fragment designed to encompass the region just upstream of the ATG start-codon. The 2.5-kb fragment obtained was ligated to a cassette containing a fusion of a nuclear localization signal (NLS) in-frame with the β -galactosidase gene [kindly provided by M. Buckingham (Pasteur Institute, Paris, France)]. Downstream, we inserted the *Neomycin resistance* gene flanked by LoxP sites. Next, the fragment encompassing the former 2.5-kb 5' fragment, the NLS- β -galactosidase gene and the LoxP-*Neomycin resistance* gene was ligated upstream of an 8.1-kb *XhoI/BamHI* 3' fragment. Finally, the *Herpes simplex virus-thymidine kinase* cassette was added in the 3' position. The *XhoI* enzyme was used to linearize our construct prior to electroporation into ES cells.

Generation of mutant animals

The generation of recombinant ES clones and *Arx* mutant mice was performed as described by Mansouri (2001). A total of 202 stably transfected ES clones were obtained after antibiotic selection. Clones were screened for the presence of the disrupted *Arx* gene by Southern blotting with a 1.3-kb *HincII*-digested 5' external probe (shown in Fig. 3A). Mutant ES cells were aggregated with NMRI 8-cell-stage embryos using standard techniques. Chimeric male mice were obtained and mated to NMRI females to generate heterozygous animals. Mice were genotyped by PCR using a mixture of three primers (Fig. 2A) to identify the wild-type and the mutant alleles, generating a 0.25-kb and a 0.4-kb PCR product, respectively (P1, CGGCTCAC TACACTTGTTACCGCTTGTCC; P2, AGCAGCCCTCTTCC TGGTACTGATTGCTC; and P3, TGCTGCAAGGCGATAAG TTGGGTAACGC).

β -galactosidase staining

Whole embryos or tissues were isolated and the yolk sac saved for DNA preparation and genotyping. After fixation in 4% paraformaldehyde, embryos and tissues were washed in PBS and then incubated in staining solution [4 mM K₃[Fe(CN)₆], 4 mM K₄[Fe(CN)₆], 0.02% NP-40, 0.01% Na-deoxycholate, 5 mM EGTA, 2 mM MgCl₂, and 0.4 mg/mL 5-bromo-4-chloro-3-indolyl-D-galactopyranoside. Prior to sectioning, tissues were dehydrated through ethanol series, cleared in toluene, and embedded in paraffin.

Hematoxylin-eosin staining

Paraformaldehyde-fixed tissues, embedded in paraffin, were cut in 6- μ m sections and applied to Probe-on Plus slides (Fisher Scientific). Tissues were incubated after rehydration in hematoxylin for 2.5 min, rinsed in water, dipped quickly in 0.5% HCl/70% ethanol (v/v), and washed in water. After immersion in 0.2% NaHCO₃, they were rinsed in water, dipped in 0.1% eosin for 20 sec, and washed briefly in water before dehydration and mounting.

RNA in situ hybridization

For whole-mount RNA in situ hybridization, tissues were isolated, fixed in 4% paraformaldehyde, and dehydrated through methanol series. Rehydrated embryos were bleached in 6%

H₂O₂ for 1 h, permeabilized with 10 μ g/mL proteinase K for 1–15 min, and prehybridized at 70°C for 90 min in a medium containing 50% formamide, 5 $\times$ SSC at pH 4.5, 50 μ g/mL yeast tRNA, 50 μ g/mL heparin. Hybridization was performed overnight under the same conditions. For RNA in situ hybridization on sections, embryos were collected, fixed, incubated overnight in 30% sucrose, embedded in cryomatrix, and 10- μ m sections were applied to Probe-on Plus slides (Fisher Scientific). Defrosted sections were hybridized overnight with DIG-labeled probes in a medium containing 50% formamide, 10% dextran sulphate, 1 mg/mL yeast tRNA, 0.02% BSA, 0.02% Ficoll, and 0.02% PVP.

Embryos and sectioned tissues were washed successively in 50% formamide, 1 $\times$ SSC, 0.1% Tween-20 at 70°C for 70 min, and MABT at pH 7.5 (100 mM maleic acid; 150 mM NaCl; 0.1% Tween-20) at room temperature for 1 h and blocked in PBS containing 20% inactivated fetal calf serum for 90 min. Anti-DIG antibody (1:2500) was applied overnight in the same solution at room temperature. Tissues were washed thoroughly in MABT for 2 h, rinsed with NTMT (100 mM NaCl; 100 mM Tris-HCl at pH 9.5; 50 mM MgCl₂; 1% Tween-20) for 1 h, stained in a solution containing 350 μ g/mL NBT, 175 μ g/mL BCIP, rinsed in PBS, and fixed in 4% paraformaldehyde. The *Arx* cRNA probe used was transcribed from a PCR-generated fragment encompassing the 8–1168-bp region of *Arx* full-length cDNA. The β -galactosidase cRNA PCR-generated probe contains the 675–1140-bp portion of the β -galactosidase cDNA.

Immunohistochemistry

Tissues were fixed in 4% paraformaldehyde, embedded in paraffin and 6- μ m sections were applied to Probe-on Plus slides (Fisher Scientific). Deparaffinized and rehydrated sections were permeabilized in 0.2% Triton X-100 for 5 min and blocked in PBS containing 10% inactivated fetal calf serum for 90 min. Primary antibodies were diluted in the same medium, applied on sections, and incubated overnight at 4°C. Slides were washed in PBS and incubated for 90 min with the appropriate secondary antibody diluted in PBS containing 10% inactivated fetal calf serum. Slides were washed in PBS, mounted with DAPI, and viewed by fluorescent microscopy. Sections that had been subjected to in situ hybridization were washed in PBS, blocked, and incubated with primary antibodies as described above.

The primary antibodies used in these assays were as follows: mouse monoclonal anti-insulin diluted 1/1000 (Sigma); mouse monoclonal anti-glucagon diluted 1/1000 (Sigma); guinea-pig anti-insulin diluted 1/1000 (Sigma); guinea-pig anti-glucagon diluted 1/1000 (Sigma); rabbit anti-somatostatin diluted 1/600 (Dako); rabbit anti-PP diluted 1/200 (Dako); rabbit anti- β -galactosidase diluted 1/300 (Molecular Probes); mouse anti- β -galactosidase diluted 1/5000 (Promega); rabbit anti-*Nkx6.1* diluted 1/3000; rabbit anti-*Pdx1* diluted 1/2000 [kindly provided by C. Wright (Vanderbilt University, Nashville, TN)]; rabbit anti-*Isl1* diluted 1/2000 [kindly provided by T. Jessell (Columbia University, New York)]; rabbit anti-Hb9 diluted 1/10000 [kindly provided by T. Jessell]; rabbit anti-*Nkx2.2* diluted 1/1000 [kindly provided by T. Jessell]; rabbit anti-*Pax6* diluted 1/500 [kindly provided by S. Saule (UMR 146, Orsay, France)]; rabbit anti-*Ngn3* diluted 1/2000 [kindly provided by M. German (Diabetes Center, San Francisco, CA)]; and rabbit anti-*Arx* diluted 1/4500.

The secondary antibodies (Molecular Probes, dilution 1/1000) used for immunofluorescence were as follows: 594-alexa anti-mouse; 488-alexa anti-mouse; 594-alexa anti-rabbit; 488-alexa anti-rabbit; 594-alexa anti-guinea pig; and 488-alexa anti-guinea pig.

Glucose levels

Glucose levels were determined with the One Touch Glucose monitoring kit (Johnson & Johnson) using 15 μ L of peripheral blood from 0.5-, 1-, and 2-day-old mice. Blood glucose levels are represented as an average $\pm$ standard deviation.

RNA isolation and cDNA synthesis

RNA was isolated by lysing tissues in guanidinium thiocyanate/phenol buffer (Trizol; Invitrogen) according to the manufacturer's instructions. After resuspension in RNase-free water, ethanol precipitation, and wash in 70% ethanol, the total RNA was diluted in RNase-free water to 2 μ g/ μ L. cDNA synthesis was performed with the superscript single-stranded cDNA synthesis kit (Invitrogen) according to manufacturer's instructions. Briefly, 10 μ g of total RNA were denatured at 70°C for 10 min, quickly chilled on ice, and subjected to cDNA synthesis at 45°C for 1 h.

RT-PCR and multiplex RT-PCR reactions

RT-PCR were carried out in 50- μ L reactions using 0.5 μ L of the diluted cDNA product as template with 47 μ L of PCR mix (Genecraft); 10 pM of each primer and 2.5 U of *Taq* polymerase (Genecraft). Multiplex RT-PCR reactions were performed strictly following the protocol described by Jensen et al. (1996) by use of primers derived from *insulin*, *glucagon*, *somatostatin*, α -*tubulin* (data not shown), *TATA-box-binding protein*, *Arx*, and *Pax4* genes. Previously unmentioned primers and multiplex RT-PCR conditions were as follows: *Arx* 5'Oligo (CAG CATTGGCAGGCTCT) and 3'oligo (AGGATGTTGAGCT GCGTGAG), producing a 178-bp PCR product (26 cycles), and *Pax4* 5'Oligo (ACCTCATCCCAGGCCTATCT) and 3'oligo (AGGCCTCTTATGGCCAGTTT), producing a 220-bp PCR product (25 cycles). Reaction products labeled with [α -³²P]dCTP (Amersham) were separated on 6% polyacrylamide gels, dried, and exposed overnight to a phosphorimage storage screen. Screens were subsequently scanned by a Molecular Dynamics PhosphorImager Series 400, and band intensities were calculated using the Imagequant software with rectangle mode/local background/volume integration. All amplicons were measured against the internal standards TATA-box-binding protein.

Preparation of polyclonal antibodies

Rabbits were injected with a mixture of three peptides corresponding to amino acids 2–16, 167–181, and 314–329 of *Arx* coupled to keyhole limpet hemocyanin (Eurogentec).

Acknowledgments

We are most grateful to Dr. K. Kniesel for bioinformatic assistance and Dr. X. Zhou, as well as Prof. Penicaud and Dr. F. Pituello, for helpful discussions. We thank Prof. J. Smith and Dr. G. Goudreau for careful reading of the manuscript, Dr. D. Treichel, Dr. A. Stoykova, Dr. K. Chowdhury, and our laboratory members for their constant support. We also thank S. Mahsur and U. Franke for excellent technical assistance. This work was supported by the DFG (Graduiertenkolleg 242), the Max-Planck Society, the JDRF Center for Beta Cell Therapy in Europe, and the NIH Beta Cell Biology Consortium.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

References

- Adrian, T.E., Bloom, S.R., Hermansen, K., and Iversen, J. 1978. Pancreatic polypeptide, glucagon and insulin secretion from the isolated perfused canine pancreas. *Diabetologia* **14**: 413–417.
- Ahlgren, U., Pfaff, S.L., Jessell, T.M., Edlund, T., and Edlund, H. 1997. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. *Nature* **385**: 257–260.
- Ahlgren, U., Jonsson, J., Jonsson, L., Simu, K., and Edlund, H. 1998. β -Cell-specific inactivation of the mouse *Ipfl/Pdx1* gene results in loss of the β -cell phenotype and maturity onset diabetes. *Genes & Dev.* **12**: 1763–1768.
- Apelqvist, A., Li, H., Sommer, L., Beatus, P., Anderson, D.J., Honjo, T., Hrabe de Angelis, M., Lendahl, U., and Edlund, H. 1999. Notch signalling controls pancreatic cell differentiation. *Nature* **400**: 877–881.
- Blair, H.J., Reed, V., Gormally, E., Wilson, J.B., Novak, J., McInnes, R.R., Phillips, S.J., Taylor, B.A., and Boyd, Y. 2002. Positioning of five genes (CASK, ARX, SAT, IMAGE cDNAs 248928 and 253949) from the human X chromosome short arm with respect to evolutionary breakpoints on the mouse X chromosome. *Mamm. Genome* **11**: 710–712.
- Csaba, Z. and Dournaud, P. 2001. Cellular biology of somatostatin receptors. *Neuropeptides* **35**: 1–23.
- Dohrmann, C., Gruss, P., and Lemaire, L. 2000. Pax genes and the differentiation of hormone-producing endocrine cells in the pancreas. *Mech. Dev.* **92**: 47–54.
- Edlund, H. 2002. Pancreatic organogenesis-developmental mechanisms and implications for therapy. *Nat. Rev. Genet.* **3**: 524–532.
- Gradwohl, G., Dierich, A., LeMeur, M., and Guillemot, F. 2000. *neurogenin3* is required for the development of the four endocrine cell lineages of the pancreas. *Proc. Natl. Acad. Sci.* **97**: 1607–1611.
- Gu, G., Dubauskaite, J., and Melton, D.A. 2002. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. *Development* **129**: 2447–2457.
- Guz, Y., Montminy, M.R., Stein, R., Leonard, J., Gamer, L.W., Wright, C.V., and Teitelman, G. 1995. Expression of murine STF-1, a putative insulin gene transcription factor, in β cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. *Development* **121**: 11–18.
- Harrison, K.A., Druey, K.M., Deguchi, Y., Tuscano, J.M., and Kehrl, J.H. 1994. A novel human homeobox gene distantly related to proboscipedia is expressed in lymphoid and pancreatic tissues. *J. Biol. Chem.* **269**: 19968–19975.
- Herrera, P.L. 2000. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. *Development* **127**: 2317–2322.
- Herrera, P.L., Huarte, J., Sanvito, F., Meda, P., Orci, L., and Vassalli, J.D. 1991. Embryogenesis of the murine endocrine pancreas; early expression of pancreatic polypeptide gene. *Development* **113**: 1257–1265.
- Hirose, S. and Mitsudome, A. 2003. X-linked mental retardation and epilepsy: Pathogenic significance of ARX mutations. *Brain. Dev.* **25**: 161–165.
- Huotari, M.A., Miettinen, P.J., Palgi, J., Koivisto, T., Ustinov, J., Harari, D., Yarden, Y., and Otonkoski, T. 2002. ErbB signalling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture. *Endocrinology* **143**: 4437–4446.
- Hussain, M.A., Lee, J., Miller, C.P., and Habener, J.F. 1997. POU domain transcription factor brain 4 confers pancreatic α -cell-

- specific expression of the proglucagon gene through interaction with a novel proximal promoter G1 element. *Mol. Cell. Biol.* **17**: 7186–7194.
- Hussain, M.A., Miller, C.P., and Habener, J.F. 2002. Brn-4 transcription factor expression targeted to the early developing mouse pancreas induces ectopic glucagon gene expression in insulin-producing β cells. *J. Biol. Chem.* **277**: 16028–16032.
- Jensen, J., Serup, P., Karlsen, C., Funder-Nielsen, T., and Madsen, O.D. 1996. mRNA profiling of rat islet tumors reveals Nkx6.1 as a β -cell-specific homeodomain transcription factor. *J. Biol. Chem.* **271**: 18749–18758.
- Jensen, J., Heller, R.S., Funder-Nielsen, T., Pedersen, E.E., Lindsell, C., Weinmaster, G., Madsen, O.D., and Serup, P. 2000. Independent development of pancreatic α - and β -cells from neurogenin3-expressing precursors: A role for the notch pathway in repression of premature differentiation. *Diabetes* **49**: 163–176.
- Jonsson, J., Carlsson, L., Edlund, T., and Edlund, H. 1994. Insulin-promoter-factor 1 is required for pancreas development in mice. *Nature* **371**: 606–609.
- Kitamura, K., Yanazawa, M., Sugiyama, N., Miura, H., Iizuka-Kogo, A., Kusaka, M., Omichi, K., Suzuki, R., Kato-Fukui, Y., Kamiirisa, K., et al. 2002. Mutation of *ARX* causes abnormal development of forebrain and testes in mice and X-linked lissencephaly with abnormal genitalia in humans. *Nat. Genet.* **32**: 359–369.
- Li, H., Arber, S., Jessell, T.M., and Edlund, H. 1999. Selective agenesis of the dorsal pancreas in mice lacking homeobox gene *Hlxb9*. *Nat. Genet.* **23**: 67–70.
- Mansouri, A. 2001. Determination of gene function by homologous recombination using embryonic stem cells and knockout mice. *Methods Mol. Biol.* **175**: 397–413.
- Mansouri, A., St-Onge, L., and Gruss, P. 1999. Role of *Pax* genes in endoderm-derived organs. *Trends Endocrinol. Metab.* **10**: 164–167.
- Miura, H., Yanazawa, M., Kato, K., and Kitamura, K. 1997. Expression of a novel *aristaless* related homeobox gene '*Arx*' in the vertebrate telencephalon, diencephalon and floor plate. *Mech. Dev.* **65**: 99–109.
- Offield, M.F., Jetton, T.L., Labosky, P.A., Ray, M., Stein, R.W., Magnuson, M.A., Hogan, B.L., and Wright, C.V. 1996. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. *Development* **122**: 983–995.
- Oster, A., Jensen, J., Serup, P., Galante, P., Madsen, O.D., and Larsson, L.I. 1998. Rat endocrine pancreatic development in relation to two homeobox gene products (Pdx-1 and Nkx 6.1). *J. Histochem. Cytochem.* **46**: 707–715.
- Pictet, R.L., Clark, W.R., Williams, R.H., and Rutter, W.J. 1972. An ultrastructural analysis of the developing embryonic pancreas. *Dev. Biol.* **29**: 436–467.
- Roncoroni, L., Violi, V., Montanari, M., and Muri, M. 1983. Effect of somatostatin on exocrine pancreas evaluated on a total external pancreatic fistula of neoplastic origin. *Am. J. Gastroenterol.* **78**: 425–428.
- Sander, M., Neubuser, A., Kalamaras, J., Ee, H.C., Martin, G.R., and German, M.S. 1997. Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. *Genes & Dev.* **11**: 1662–1673.
- Sander, M., Sussel, L., Connors, J., Scheel, D., Kalamaras, J., Dela Cruz, F., Schwitzgebel, V., Hayes-Jordan, A., and German, M. 2000. Homeobox gene *Nkx6.1* lies downstream of *Nkx2.2* in the major pathway of β -cell formation in the pancreas. *Development* **127**: 5533–5540.
- Schwitzgebel, V.M., Scheel, D.W., Connors, J.R., Kalamaras, J., Lee, J.E., Anderson, D.J., Sussel, L., Johnson, J.D., and German, M.S. 2000. Expression of neurogenin3 reveals an islet cell precursor population in the pancreas. *Development* **127**: 3533–3542.
- Slack, J.M. 1995. Developmental biology of the pancreas. *Development* **121**: 1569–1580.
- Smith, S.B., Ee, H.C., Connors, J.R., and German, M.S. 1999. Paired-homeodomain transcription factor PAX4 acts as a transcriptional repressor in early pancreatic development. *Mol. Cell. Biol.* **19**: 8272–8280.
- Sommer, L., Ma, Q., and Anderson, D.J. 1996. *neurogenins*, a novel family of *atonal*-related bHLH transcription factors, are putative mammalian neuronal determination genes that reveal progenitor cell heterogeneity in the developing CNS and PNS. *Mol. Cell. Neurosci.* **8**: 221–241.
- Sosa-Pineda, B., Chowdhury, K., Torres, M., Oliver, G., and Gruss, P. 1997. The *Pax4* gene is essential for differentiation of insulin-producing β cells in the mammalian pancreas. *Nature* **386**: 399–402.
- St-Onge, L., Sosa-Pineda, B., Chowdhury, K., Mansouri, A., and Gruss, P. 1997. *Pax6* is required for differentiation of glucagon-producing α -cells in mouse pancreas. *Nature* **387**: 406–409.
- Sussel, L., Kalamaras, J., Hartigan-O'Connor, D.J., Meneses, J.J., Pedersen, R.A., Rubenstein, J.L., and German, M.S. 1998. Mice lacking the homeodomain transcription factor *Nkx2.2* have diabetes due to arrested differentiation of pancreatic β cells. *Development* **125**: 2213–2221.
- Teitelman, G., Alpert, S., Polak, J.M., Martinez, A., and Hana-han, D. 1993. Precursor cells of mouse endocrine pancreas coexpress insulin, glucagon and the neuronal proteins tyrosine hydroxylase and neuropeptide Y, but not pancreatic polypeptide. *Development* **118**: 1031–1039.
- Upchurch, B.H., Aponte, G.W., and Leiter, A.B. 1994. Expression of peptide YY in all four islet cell types in the developing mouse pancreas suggests a common peptide YY-producing progenitor. *Development* **120**: 245–252.

Opposing actions of Arx and Pax4 in endocrine pancreas development

Patrick Collombat, Ahmed Mansouri, Jacob Hecksher-Sørensen, et al.

Genes Dev. 2003, **17**:

Access the most recent version at doi:[10.1101/gad.269003](https://doi.org/10.1101/gad.269003)

References

This article cites 40 articles, 19 of which can be accessed free at:
<http://genesdev.cshlp.org/content/17/20/2591.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).